Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference

GlobeNewswire

昨天

ptx-logo .png

WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27^th Annual Global Healthcare Conference, taking place in Miami, FL on March 11, 2025.

On Tuesday, March 11, 2025, at 12:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Bryant Lim, Chief Financial Officer will participate in a fireside chat.

A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.

About Prelude Therapeutics

Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.

Investor Contact:
Robert Doody
Senior Vice President, Investor Relations
Prelude Therapeutics
484.639.7235
RDoody@preludetx.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2517221916"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2517221916\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2517221916?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-05 20:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2517221916","market":"us","top_or_hot":-1,"title":"Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/sOEOFiQtzhhQVN.OAAubQQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/8835d8a0be4b67686e42408eafbca555\" title=\"ptx-logo .png\" vspace=\"5\"/>\n<p>WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27<sup>th</sup> Annual Global Healthcare Conference, taking place in Miami, FL on March 11, 2025.</p>\n<p>On Tuesday, March 11, 2025, at 12:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Bryant Lim, Chief Financial Officer will participate in a fireside chat.</p>\n<p>A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.</p>\n<p><strong><em>About Prelude Therapeutics</em></strong><em> </em></p>\n<p>Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.</p>\n<p><strong>Investor Contact:</strong> <br/>Robert Doody <br/>Senior Vice President, Investor Relations <br/>Prelude Therapeutics<br/>484.639.7235<br/>RDoody@preludetx.com<br/><br/><br/><br/><br/><br/></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference\n</h2>\n<h4 class=\"meta\">\n</h4><p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2025-03-05 20:30</span>\n</p>\n</header>\n<article>\n<img hspace=\"5\" src=\"https://s.yimg.com/uu/api/res/1.2/sOEOFiQtzhhQVN.OAAubQQ--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/8835d8a0be4b67686e42408eafbca555\" title=\"ptx-logo .png\" vspace=\"5\"/>\n<p>WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27<sup>th</sup> Annual Global Healthcare Conference, taking place in Miami, FL on March 11, 2025.</p>\n<p>On Tuesday, March 11, 2025, at 12:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Bryant Lim, Chief Financial Officer will participate in a fireside chat.</p>\n<p>A live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.</p>\n<p><strong><em>About Prelude Therapeutics</em></strong><em> </em></p>\n<p>Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.</p>\n<p><strong>Investor Contact:</strong> <br/>Robert Doody <br/>Senior Vice President, Investor Relations <br/>Prelude Therapeutics<br/>484.639.7235<br/>RDoody@preludetx.com<br/><br/><br/><br/><br/><br/></p>\n<br/>\n<div class=\"bt-text\">\n<p> 來源：<a href=\"https://finance.yahoo.com/news/prelude-therapeutics-participate-barclays-27th-123000555.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRLD","symbol_name":"Prelude Therapeutics Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/prelude-therapeutics-participate-barclays-27th-123000555.html","article_id":"2517221916","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517221916","pubTimestamp":1741177800,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"WILMINGTON, Del., March 05, 2025  -- Prelude Therapeutics Incorporated  , a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27th Annual Global Healthcare Conference, taking place in Miami, FL on March 11, 2025.On Tuesday, March 11, 2025, at 12:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Bryant Lim, Chief Financial Officer will participate in a fireside chat.Prelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates  with partners. We ar","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRLD":"Prelude Therapeutics Inc","HCSG":"医疗保健服务","LENZ":"Therapeutics","BK4137":"综合支持服务","BK4505":"高瓴资本持仓","BK4139":"生物科技"},"translate_title":"Prelude Therapeutics将参加巴克莱第27届全球医疗保健年会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCSG":1,"LENZ":1,"PRLD":1},"content_text":"WILMINGTON, Del., March 05, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Barclays 27th Annual Global Healthcare Conference, taking place in Miami, FL on March 11, 2025.\nOn Tuesday, March 11, 2025, at 12:30 p.m. ET, Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, Jane Huang, M.D., President and Chief Medical Officer, and Bryant Lim, Chief Financial Officer will participate in a fireside chat.\nA live webcast of the fireside chat can be accessed on the Company’s website under Events and Presentations. The recording will be archived and available on the Company’s website for 90 days.\nAbout Prelude Therapeutics \nPrelude Therapeutics is a leading precision oncology company developing innovative medicines in areas of high unmet need for cancer patients. Our pipeline is comprised of several novel drug candidates including first-in-class, highly selective IV and oral SMARCA2 degraders, and a potentially best-in-class CDK9 inhibitor. We are also leveraging our expertise in targeted protein degradation to discover, develop and commercialize next generation degrader antibody conjugates (Precision ADCs) with partners. We are on a mission to extend the promise of precision medicine to every cancer patient in need. For more information, visit preludetx.com.\nInvestor Contact: Robert Doody Senior Vice President, Investor Relations Prelude Therapeutics484.639.7235RDoody@preludetx.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":1}}}